173 related articles for article (PubMed ID: 34508752)
1. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
Corboz MR; Plaunt AJ; Malinin V; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
Eur J Pharmacol; 2022 Feb; 916():174484. PubMed ID: 34508752
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
[TBL] [Abstract][Full Text] [Related]
3. Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats.
Chapman RW; Li Z; Chun D; Gauani H; Malinin V; Plaunt AJ; Cipolla D; Perkins WR; Corboz MR
Pulm Pharmacol Ther; 2021 Feb; 66():101983. PubMed ID: 33346142
[TBL] [Abstract][Full Text] [Related]
4. Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension.
Plaunt AJ; Islam S; Macaluso T; Gauani H; Baker T; Chun D; Viramontes V; Chang C; Corboz MR; Chapman RW; Li Z; Cipolla DC; Perkins WR; Malinin VS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430435
[TBL] [Abstract][Full Text] [Related]
5. An overview of the biology of a long-acting inhaled treprostinil prodrug.
Chapman RW; Corboz MR; Malinin VS; Plaunt AJ; Konicek DM; Li Z; Perkins WR
Pulm Pharmacol Ther; 2020 Dec; 65():102002. PubMed ID: 33596473
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
Chaudhary KR; Deng Y; Suen CM; Taha M; Petersen TH; Mei SHJ; Stewart DJ
Br J Pharmacol; 2018 Oct; 175(20):3976-3989. PubMed ID: 30098019
[TBL] [Abstract][Full Text] [Related]
7. Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.
Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
Am J Physiol Lung Cell Mol Physiol; 2019 Jan; 316(1):L119-L130. PubMed ID: 30307312
[TBL] [Abstract][Full Text] [Related]
8. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.
Christou H; Hudalla H; Michael Z; Filatava EJ; Li J; Zhu M; Possomato-Vieira JS; Dias-Junior C; Kourembanas S; Khalil RA
J Pharmacol Exp Ther; 2018 Feb; 364(2):258-274. PubMed ID: 29212831
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Mendes-Ferreira P; Adão R; Brás-Silva C; Kinsella BT
Eur J Pharmacol; 2020 Dec; 889():173658. PubMed ID: 33121950
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
[TBL] [Abstract][Full Text] [Related]
12. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).
Rashid J; Patel B; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
J Control Release; 2017 Mar; 250():96-106. PubMed ID: 28185800
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
14.
Peng Y; Dai J; Zhao YY
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768713
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.
Corboz MR; Li Z; Malinin V; Plaunt AJ; Konicek DM; Leifer FG; Chen KJ; Laurent CE; Yin H; Biernat MC; Salvail D; Zhuang J; Xu F; Curran A; Perkins WR; Chapman RW
J Pharmacol Exp Ther; 2017 Dec; 363(3):348-357. PubMed ID: 28904003
[TBL] [Abstract][Full Text] [Related]
16. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
17. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension.
Klinger JR; Thaker S; Houtchens J; Preston IR; Hill NS; Farber HW
Chest; 2006 Feb; 129(2):417-425. PubMed ID: 16478861
[TBL] [Abstract][Full Text] [Related]
19. Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil.
Chapman RW; Li Z; Corboz MR; Gauani H; Plaunt AJ; Konicek DM; Leifer FG; Laurent CE; Yin H; Salvail D; Dziak C; Perkins WR; Malinin V
Pulm Pharmacol Ther; 2018 Apr; 49():104-111. PubMed ID: 29421665
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
Ismat FA; Usansky HH; Villa R; Zou J; Teper A
Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
